Zevra Therapeutics
Denmark - FrederiksbergBiotechnology
Focus: Zevra Therapeutics is a Danish biotech company specializing in modifications of existing drugs, focusing on rare disease indications. They operate as a publicly traded mid-cap biotech with a marketed opioid combination product and a pipeline of repurposed/reformulated therapies.
Profile data last refreshed 11h ago · AI intelligence enriched 2w ago
Open Jobs
10-2 this month
Stable — net -2 jobs in 30d
0 added, 2 removed. Backfill posture.
Should You Work at Zevra Therapeutics?
AI assessmentZevra offers rare disease focus and clinical pipeline depth, but limited financial transparency and recent corporate signals warrant careful evaluation of stability and growth runway.
Why Work Here
- APADAZ (benzhydrocodone/acetaminophen) is at peak lifecycle with LOE protection until 2031, providing revenue stability and commercial execution visibility.
Data completeness
6/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
1 in 5yr
APADAZ
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Peak4.3yr
Only marketed product; provides revenue base and commercial infrastructure for rare disease pipeline support through 2031 LOE.
Help build intelligence for Zevra Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.